The PATHFINDER Study: A Feasibility Trial

NCT04016740 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease
Delirium

Interventions

DRUG: Ropivacaine
DRUG: Ketamine
DRUG: Remifentanil
DRUG: Dexmedetomidine
DRUG: Rocuronium
DRUG: Propofol
DRUG: Sevoflurane
DRUG: Dexmedetomidine
DRUG: Propofol
DEVICE: EEG monitoring

Sponsor

Beth Israel Deaconess Medical Center